Form 4: Bicycle Therapeutics CTO Sells Shares for Tax Obligations
Insider Transaction Report
Bicycle Therapeutics PLC's Chief Technology Officer, Michael Skynner, sold a total of 1,791 ordinary shares in non-discretionary 'sell to cover' transactions to satisfy tax withholding obligations.
Summary
- Michael Skynner, Chief Technology Officer of Bicycle Therapeutics PLC, reported two sales of ordinary shares.
- On July 2, 2025, 825 ordinary shares were sold at a weighted average price of $7.09 per share, with prices ranging from $7.09 to $7.14.
- On July 3, 2025, an additional 966 ordinary shares were sold at a weighted average price of $7.44 per share, with prices ranging from $7.405 to $7.44.
- These sales were non-discretionary 'sell to cover' transactions, mandated to satisfy statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units.
- Following these transactions, Michael Skynner beneficially owns 120,079 ordinary shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions are non-discretionary 'sell to cover' sales for tax purposes, which are routine and not indicative of management's view on the company's prospects.
Future Outlook
The document does not provide any forward-looking statements or guidance.
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction, specifically a 'sell to cover' sale, which is common for executives in the biotechnology industry receiving equity compensation. It does not reflect broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: The sale is a routine, non-discretionary transaction for tax purposes and is unlikely to have a significant impact on shareholder perception or company valuation.
Key Dates
| Date | Description |
|---|---|
| 07/02/2025 | Transaction date for the sale of 825 ordinary shares. |
| 07/03/2025 | Transaction date for the sale of 966 ordinary shares. |
| 07/07/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Recommendation
holdKeywords
Bicycle Therapeutics PLC, BCYC, Form 4, Insider Transaction, Share Sale, Restricted Stock Units, Tax Withholding, Michael Skynner, Chief Technology Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.